Clinical trial

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

NCT06667622

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention sodium glycididazole Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2024-05-29

PhasePHASE2

Conditions

Chemoradiotherapyunresolved

Interventions

sodium glycididazoleDRUG

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06667622 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.